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Abstract 
Background: Human endogenous retroviruses (HERVs) are genomic sequences of retroviral origin which were 
believed to be integrated into germline chromosomes millions of years ago and account for nearly 8% of the human 
genome. Although mostly defective and inactive, some of the HERVs may be activated under certain physiological 
and pathological conditions. While no drugs are designed specifically targeting HERVs, there are a panel of antiretro-
viral drugs designed against the human immunodeficiency virus and approved by the Federal Drug Administration 
(FDA).
Results: We determined if these antiretroviral drugs may also be effective in inhibiting HERVs. We constructed a 
plasmid with consensus HERV-K sequence for testing the effect of antiretroviral drugs on HERV-K. We first determined 
the effects of nucleoside and non-nucleotide reverse transcriptase (RT) inhibitors on HERV-K by product enhanced 
reverse transcription assay. We found that all RT inhibitors could significantly inhibit HERV-K RT activity. To determine 
the effects of antiretroviral drugs on HERV-K infection and viral production, we pseudotyped HERV-K with VSV-G and 
used the pseudotyped HERV-K virus to infect HeLa cells. HERV-K production was measured by quantitative real time 
polymerase chain reaction. We found that RT inhibitors Abacavir and Zidovudine, and integrase inhibitor Raltegravir 
could effectively block HERV-K infection and production. However, protease inhibitors were not as effective as RT and 
integrase inhibitors.
Conclusions: In summary, we identified several FDA approved antiretroviral drugs that can effectively inhibit HERV-K. 
These antiretrovirals may open new prospects for studying HERV-K pathophysiology and potentially for exploring 
treatment of diseases in which HERV-K has been implicated.
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Background
Tremendous progress has been made in the develop-
ment of antiretroviral drugs that target HIV replication. 
Initial drugs targeted reverse transcriptase (RT), however 
now drugs are available that target all major parts of the 
viral life cycle. This includes blockage at viral entry, inte-
grase (IN) inhibitors that prevent integration of proviral 
DNA into the chromosomal DNA, protease inhibitors 
that prevent cleavage of the Gag–Pol polyprotein and 
maturation inhibitors. However, the effect of these drugs 
on endogenous retroviruses (ERV) remains unknown. 
ERV’s constitute nearly 8% of the human genome. While 
they play an important role in embryonic development 
[1], they remain silent in adults. Under pathological cir-
cumstances, these viral elements may get reactivated. 
For example, we previously showed that in patients 
with amyotrophic lateral sclerosis (ALS), human ERV-K 
(HERV-K) was expressed and this activation causes neu-
rotoxicity [2, 3]. Hence it would be important to know 
if inhibition of HERV-K could alter the course of ALS. 
HERV-K activation has also been associated with schizo-
phrenia and some cancers [4–7]. HERV-K is a beta-ret-
rovirus. It has similarity to lentivirus HIV including 5′ 
and 3′ LTR region, an envelope (env), gag and pol genes. 
HERV-K is the most recently acquired ERV in the human 
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genome and hence has several intact open reading frames 
[8]. The pol gene encodes RT, protease and IN. Rec pro-
tein is encoded from an alternative spliced messenger 
RNA from env and is similar in function to Rev protein 
of HIV. In some HERV-K sequences there is a deletion of 
292 base pairs at the pol–env junction as a result Rec is 
not formed [8]. This resulted in an mRNA for a ~9 kDa 
fusion protein referred to as Np9, the function of which 
is not yet understood. HERV-K lacks the other regula-
tory genes such as tat, nef, vpr and vpu which are pre-
sent in the HIV genome. Since HERV-K has its own RT, 
protease and IN, we screened a panel of FDA approved 
anti-HIV drugs that target these enzymes, for their ability 
to inhibit HERV-K.
Results
Viral particle production with consensus HERV‑K genome
To generate HERV-K viral particles for determining the 
effects of antiretroviral drugs on HERV-K, a consensus 
HERV-K sequence [9] was synthesized and subcloned 
into pcDNA 3.1 vector. Because HIV-1 Rev can signifi-
cantly enhance the transcription of HERV-K viral gene, 
an HIV-1 Rev expression cassette was also inserted 
into the construct which we have termed pCD-HK/Rev 
(Fig. 1a). After transfection of either HeLa or 293T cells 
with pCD-HK/Rev and pCD-Tat plasmid, the produc-
tion of viral particles was confirmed by electron micros-
copy [9]. The amount of viral production was quantified 
by measuring RT activity in the culture supernatant 
with PERT assay (Fig. 1bi). Recombinant HIV-1 RT was 
used as a positive control and to make a standard curve 
(Fig.  1bii). The HERV-K RT quantification using this 
standard curve is only relative to HIV RT, not an abso-
lute RT activity. HERV-K viral particles released to the 
culture media increased until 48 h after transfection, and 
plateaued at 72 h. To further confirm HERV-K viral gene 
expression, cell lysate was collected 48  h post-transfec-
tion. The expression of HERV-K Env and Gag was deter-
mined by Western blot analysis (Figs.  1c, 7d). The Gag 
antibody recognized both precursor Gag (70  kDa) and 
mature Gag (27  kDa) proteins [10]. The Env antibody 
recognized both full-length (80 kDa) Env and the trans-
membrane subunit (42 kDa). We further immunostained 
HERV-K Gag and Pol in HERV-K plasmid transfected 
293T cells (Fig. 1d). As shown in the “HERV-K transfec-
tion” panel, some cells co-expressed HERV-K Gag and 
Pol while other cells expressed only Gag or Pol.
Direct inhibition of HERV‑K reverse transcriptase (RT) 
by HIV‑1 RT inhibitors
We first tested the effects of HIV-1 RT inhibitors on 
HERV-K RT enzyme activity in a cell-free system. Viral 
particles were harvested from either HeLa or 293T 
culture media after transfection with HERV-K plasmid. 
HERV-K RT was then released from culture media by 
treatment with Triton X-100. PERT assay was used to 
determine the activity of HERV-K RT. Serial dilutions 
of inhibitors were added to the extracted HERV-K RT 
just prior to the PERT assay. We tested the following 
nucleotide RT inhibitors: tenofovir, abacavir, stavudine, 
lamivudine, and zidovudine. As shown in Fig.  2a, all 
nucleotide RT inhibitors showed significant and dose-
dependent inhibition of HERV-K RT. They had similar 
dosage-response curves and IC90 values. We also tested 
non-nucleotide inhibitors efavirenz, etravirine, and nevi-
rapine on HERV-K RT. These drugs also showed signifi-
cant inhibition of HERV-K RT activity with similar IC90 
values (Fig. 2b).
Inhibition of HERV‑K by HIV‑1 RT inhibitors
To determine the effects of RT inhibitors on HERV-K 
infection, we generated HERV-K viral particles with 
VSV-G pseudotype to facilitate infection of HERV-K in 
HeLa cells. VSV-G pseudotyped HERV-K viral particles 
allow efficient infection of most cell types while replica-
tion of HERV-K inside the cells is not altered by VSV-G 
protein. To normalize the amount of viral particles used 
for infection, recombinant HIV-1 RT was used as equiv-
alent of HERV-K RT to generate a standard curve for the 
PERT assay. HERV-K viral particles were then expressed 
as the amount of equivalent RT. Infection of HERV-K 
and viral production was determined by quantitative 
polymerase chain reaction (qPCR) for the gag gene. As 
shown in Fig. 3ai, after 6-days of infection in HeLa cells, 
the level of gag expression with VSV-G pseudotyped 
HERV-K showed a sevenfold increase compared to that 
of without pseudotyping. Similarly, in the 293T cells, 
the level of gag expression with VSV-G pseudotyping 
showed a 36-fold increase compared to that of without 
pseudotyping (Fig.  3aii). Western blot analysis further 
confirmed that VSV-G protein is incorporated into the 
HERV-K viral particles (Fig. 3aiii), however, VSV-G pro-
tein was further processed when it was incorporated into 
the viral particle, as indicated by a different molecular 
mass of the protein compared to that in the cell lysate. 
To test the effects of RT inhibitors on HERV-K infection, 
RT inhibitors were added to the cell culture medium 
immediately after the inoculation of VSV-G pseudo-
typed HERV-K virus. The concentration of inhibitors 
was chosen such that they did not cause toxicity to HeLa 
cells as determined by a cell viability assay. After 6 days 
of infection, HERV-K gag RNA was determined by qPCR 
as a measurement of HERV-K production. Abacavir 
(Fig. 3b) and Zidovudine (Fig. 3c) both inhibited HERV-
K in a dose-dependent manner, with IC90 of 0.175 and 
0.070 µM respectively.
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Comparative modeling of HERV‑K RT
HERV-K RT displays 21.5% sequence identity with 
HIV-1 RT (Fig.  4a). Comparative modeling of HERV-K 
RT (Fig.  4b) and its complexes with NNRTIs is shown 
using HIV-1 RT complex with Efavirenz (1JKV, Fig.  4c) 
and Nevirapine (E3QIP; Fig. 4d) as templates. The com-
plex with etravirine (Fig. 4e) was modeled ab initio using 
the others as guides. These drugs bind to an allosteric 
site in a hydrophobic cavity (NNRTI binding pocket) 
nearby the RT motif YIDD that interacts with the DNA. 
The model shows that most of the residues that line the 
cavity are not conserved. However, the small inhibitors 
Efavirenz and nevirapine (Fig.  4c, d, respectively) still 
can be docked snuggly inside the cavity. The large etra-
virine showed steric clashes of its benzonitrile side chain 
and central ring amine substituent with the RT. However, 
Fig. 1 Consensus HERV-K has the ability to generate active viral particles. a The consensus complete HERV-K genomic sequence was cloned into 
the pcDNA3.1 vector with HIV-1 Rev resulting in a plasmid termed pCD-HK/Rev. bi HeLa cells were transfected with the pCD-HK/Rev plasmid in 
combination with plasmids for HIV-1 Tat. The reverse transcriptase (RT) activity in the culture supernatant was determined by PERT assay at 24, 
48 and 72 h post-transfection. ii Recombinant HIV RT was diluted serially in culture media and used as an activity standard. HERV-K RT activity in i 
was quantified using this standard. c Western blot analyses for HERV-K Env expression in 293T cells after transfection with pCD-HK/Rev. d HERV-K 
transfected or mock transfected cells were fixed 24 h post-transfection and immunostained with primary antibodies for HERV-K Gag and HERV-K 
Pol. Alexa 488-conjugated goat anti-rabbit IgG and Alexa 594-conjugated goat anti-mouse IgG were used as secondary antibodies
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with small protein adjustment, etravirine could still fit 
within the cavity.
Inhibition of HERV‑K by HIV‑1 protease inhibitors
Although HERV-K protease has only 20% amino acid 
homology with HIV-1 protease (Fig. 5a), their core func-
tional domains share similar structures. Comparative 
modeling of this core showed that the residues centered 
at the active site cavity and participating in the dimer 
interface are fully conserved between these proteases 
(Fig. 5b, c). The residues participating in the dimer con-
tacts at the tip of the hairpin that forms the protease 
flap domain show high conservation. However HERV-
K has an insertion in the N-terminal region of the flap 
that may impact its flexibility (Fig.  5c). This flexibility 
has been long recognized to play a role in inhibitor/sub-
strate binding. At S1 (amino acids 87–91) and S2 (amino 
acids 30, 31, 52, 91) and their symmetry related S1′ and 
S2′ pockets, residue changes for larger residues reduce 
the size of the catalytic site. Most of these changes con-
serve hydrophobic characteristics at the site, only resi-
due 31 changes from Asp to Val. At the S1 pocket, Leu89 
and 91 replace HIV-1 smaller Val and Ile, respectively, 
reducing the size of this hydrophobic pocket (Fig.  5a, 
c). Val31, Leu53, Val53, and Leu91 replace Asp30, Ile47, 
Gly48, and Ile89 respectively reducing also the size of 
S2. However, the protease inhibitors Darunavir (Fig. 6a, 
c) and Lopinavir (Fig. 6b, d) readily dock to the protease 
catalytic site. This modeling suggests that HIV-1 pro-
teases inhibitors should have also an inhibitory effect 
on HERV-K protease, although tweaking the size of the 
groups at these pockets could positively impact drug 
inhibition. 
To determine the effect of protease inhibitors on 
HERV-K, HeLa cells were transfected with pCD-HK/
Rev and HIV-1 Tat plasmids. HIV-1 protease inhibi-
tors were added to the culture medium 6  h. after the 
transfection. PERT assay was performed 48  h after 
transfection. As shown in Fig.  7b, all protease inhibi-
tors significantly inhibited functional HERV-K viral 
production in a dose-dependent manner. Lopinavir and 
Darunavir showed the highest efficacy, with IC90 in the 
0.1 µM range. To further determine the efficacy of Lopi-
navir and Darunavir at lower dosages, more extensive 
dose–response curves were conducted. Darunavir and 
Lopinavir (Fig.  7c) both inhibited HERV-K protease 
in a dose-dependent manner, with IC90 of 0.071 and 
0.651 µM respectively. To further determine the mecha-
nism of HERV-K inhibition by protease inhibitors, 293 
cells were transfected with pCD-HK/Rev in the pres-
ence or absence of protease inhibitors, Darunavir or 
Lopinavir at a concentration of 1 µM each. After 48 h, 
HERV-K viral particles were harvested from the cul-
ture medium. The expression of Gag protein in the cell 
lysate and viral particles was examined by Western blot 
analysis. Darunavir and Lopinavir effectively blocked 
the processing of Gag (70 kDa) into mature capsid (CA) 
protein (27 kDa) both in the cell lysate and in the viral 
particles (Fig. 7d). PERT assay and viral RNA PCR were 
performed to determine if functional RT activity cor-
relates with the number of viral particles in the culture 
supernatant, As shown in Fig. 7e, PI treatment dramati-
cally blocked RT activity as shown by the PERT assay, 
while the number of viral particles as inferred by PCR 
for viral RNA had only a moderate reduction. The slight 
reduction in the number of viral particles could be 
explained by the potential toxic effect of PIs on the cells 
and/or less efficient viral release due to lack of cleavage 
of the Gag precursor protein. To examine the effect of 
PI on HERV-K infection, the harvested viral particles 
with VSV-G pseudotyping were used to infect HeLa 
cells. After 6 days of infection, gag RNA expression was 
measured by PCR. HERV-K virus with PI treatment was 
unable to replicate compared to virus without PI treat-
ment (Fig. 7e).
Fig. 2 HIV reverse transcriptase inhibitors can inhibit HERV-K reverse 
transcriptase. HERV-K supernatant was collected from Hela cells 
transfected with pCD-HK/Rev plasmid in combination with HIV-1 
Tat. HIV-RT inhibitors: a nucleoside RT inhibitors or b non-nucleotide 
RT inhibitors were added in a dose ranging from 0.05 to 0.25 µM to 
collected supernatant and PERT assay was performed to quantify 
HERV-K RT. Any change compared to no treatment was reported as 
percent inhibition
Page 5 of 13Tyagi et al. Retrovirology  (2017) 14:21 
Inhibition of HERV‑K infection by integrase inhibitor
Currently there are three FDA-approved IN inhibitors: 
Dolutegravir, Elvitegravir, and Raltegravir. We tested 
the effect of Raltegravir on HERV-K replication. VSV-G 
pseudotyped HERV-K was used to infect HeLa cells. 
Raltegravir was added immediately after viral inocula-
tion. After 6  days of infection, HERV-K gag gene was 
determined by qPCR. As shown in Fig.  3d, Raltegravir 
inhibited the replication of HERV-K in a dose-dependent 
manner, with an IC90 of 0.075 µM.
Comparative modeling of the HERV-K IN active 
site using simian prototype foamy virus (PFV) IN core 
domain as template (18% identity) [12] showed the con-
servation of the three carboxylated coordination of a 
pair of divalent metal cations (Mg2+ or Mn2+) that assist 
the nucleophilic substitution of the viral DNA (Fig.  8). 
Elvitegravir (3L3U) and raltegravir (3L2V) inhibit PFV 
INT [12]. The only active site difference between these 
enzymes, a proline to serine (Ser729) residue participates 
in these drugs recognition; however, the small change 
produced by the substitution could have little effect on 
the inhibitor recognition (Fig. 8).
Discussion
We used a consensus sequence of HERV-K for these 
studies since there are nearly 100 copies of the virus in 
the human chromosome [8] and multiple loci of HERV-
K are expressed in patients with ALS [2, 11]. Similarly 
in patients with HIV infection there is wide variability 
in viral sequences among individuals but drug develop-
ment has been successful using laboratory strains of the 
virus.
Currently there are 26 antiretroviral drugs approved 
by the FDA. Suppression of HIV infection requires the 
use of combination therapy with RT inhibitors, protease 
inhibitors, and IN inhibitors.
Fig. 3 HERV-K can be effectively inhibited by Abacavir, AZT and Raltegravir: ai Hela cells and ii 293T cells were infected with HERV-K (HK) or VSV-G 
pseudotyped HERV-K (vsv-HK) viral particles. Total RNA was extracted 6 days post-infection and quantitative PCR was used to determine HERV-K gag 
mRNA expression. Glyceraldehyde 3-phosphotate dehydrogenase (GAPDH) was used as internal control and titers were expressed as fold change. 
iii Western blot of VSV-G protein to show that VSV-G protein is incorporated into the HERV-K viral particles. b–d Hela cells were infected with 80 pg 
of VSV-G pseudotyped HERV-K virus and treated with b Abacavir, c Zidovudine (AZT) or d Raltegravir, in a dose ranging from 0.05 to 0.25 µM. Six 
days post infection gag mRNA expression was quantified using quantitative PCR. Gag expression was compared to no treatment as control and 
expressed as percent inhibition. Data represent mean ± SEM of at least 3
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The RT is critical for the replication of the viral RNA 
genome. In a reconstructed consensus HERV-K sequence, 
RT activity is critical for its replication [9, 13]. Inhibition 
with HIV RT inhibitors can significantly decrease the 
titer of infectious viral particles. RT has two enzymatic 
functions: DNA polymerase activity that synthesizes 
DNA from either a RNA or a DNA template, and RNase 
H activity that degrades the RNA strand in a RNA/DNA 
duplex. Because RT plays a central role in the viral life 
cycle, it is a key target for the development of antiretro-
viral drugs. There are two broad classes of RT inhibitors: 
nucleoside RT inhibitors (NRTIs) and non-nucleoside RT 
inhibitors (NNRTIs). NRTIs are structural analogs of the 
natural substrates of DNA polymerization. They com-
pete with the natural substrates for incorporation in viral 
DNA by RT and terminate DNA chain extension because 
of the lack of the 3′-OH group. In this study, we tested 
the following NRTIs, tenofovir, abacavir, stavudine, lami-
vudine, and zidovudine for their ability to inhibit HERV-
K RT activity and HERV-K replication. Although these 
drugs had very similar dose response curves, Abacavir 
seemed to be more potent against HERV-K compared to 
its effect on HIV  (Table  1). In comparison, Zidovudine 
was slightly less potent against HERV-K compared to its 
effects of HIV [14]. This may be important since Abacavir 
and Zidovudine have better CNS penetration compared 
to the other NRTIs [15]. However Abacavir can cause 
a hypersensitivity syndrome which is strongly but not 
exclusively associated with a specific allele at the human 
leukocyte antigen B locus namely HLA-B*57:01 [16]. 
NNRTIs do not compete with the nucleoside substrate 
of RT, instead they bind to a hydrophobic pocket close to 
the polymerase active site called NNRTI-binding pocket 
[17, 18]. Binding of NNRTI to RT affects the alignment 
of the DNA chain terminus for extension with the RT 
catalytic site and interferes the chemical synthesis of viral 
DNA [19, 20]. Efavirenz, Etravirine, and Nevirapine are 
FDA-approved NNRTIs tested in this study. These com-
pounds had similar efficacy against HERV-K however, of 
these compounds, Nevirapine has the best CNS penetra-
tion [15].
HIV protease is crucial for the maturation of viral par-
ticles. It is a homodimer and belongs to the aspartate pro-
tease family [21]. It cleaves Gag and Gag–Pol polyprotein 
precursor to produce capsid (CA) and active RT proteins. 
There are about 10 FDA-approved protease inhibitors. 
These inhibitors share similar chemical structures and 
similar binding property. They block the enzyme catalytic 
Fig. 4 Comparative modeling of HERV-K reverse transcriptase (RT) based on HIV RT. a Sequence alignment between the target and the template 
(4WE1). b Final Model of HERV-K RT showing P51 and P66 subunits. The red oval indicates the NNRTI-binding region. c–e Efavirenz, Nevirapine, 
and Etravirine, respectively bound to the NNRTI-binding pocket. Non conserved residues are colored red, green the conserved between HERV-K 
and HIV-1 RT. The NNRTIs are colored with their carbon atom in magenta. The magenta underlined sequence are residues lining the NNRTI-binding 
pocket
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site by mimicking the transition state of the real substrate 
[21].
HERV-K protease is encoded in pol gene. It belongs 
to the aspartate protease family and includes a signa-
ture motif of aspartate–threonine–aspartate similar to 
HIV protease. Its core functional domain has about 106 
amino acid residues and shares only 28% homology with 
HIV protease [22]. However modeling of the HERV-K 
protease shows similarities between the active domains 
with the HIV-protease. The protease inhibitors could be 
docked to the active domain of HERV-K protease. Con-
sistent with these observations, we found that Darunavir 
and Lopinavir were able to inhibit HERV-K replication in 
a dose-responsive manner. However the IC90 of protease 
inhibitors (Darunavir and Lopinavir) for HERV-K were 
20–50 times higher than that for HIV (Table 1). This sup-
ports the notion that protease inhibitors are more virus 
specific than RT inhibitors. A report using HERV-K10 
protease also showed that HIV protease inhibitors were 
not as effective against HERV-K protease [22]. This sug-
gests that HERV-K protease specific inhibitors may need 
to be discovered for effective antiretroviral therapy for 
HERV-K.
We found that IN inhibitor Raltegravir is highly effec-
tive against HERV-K, indicating that replication of 
HERV-K is integration dependent. IN is a key enzyme 
in the life cycle of the retrovirus and is coded in the pol 
gene. The catalytic core domain of HIV IN transfers the 
viral DNA into the chromosome with the help of both 
C- and N-terminal domains [23] HIV IN has similar 
structural similarity with other retroviral INs from avian 
sarcoma virus, rous sarcoma virus and simian immu-
nodeficiency virus, indicating they may share a simi-
lar mechanism of action [23]. Comparative modeling 
showed that there are almost no differences in the active 
site of HERV-K and simian PFV INs that can be inhibited 
by Raltegravir [12]. The inhibitors target the DNA stand 
transfer process. Hence they are called strand transfer 
inhibitors. Raltegravir is one of the FDA approved stand 
transfer inhibitors and is highly potent in inhibiting 
both HIV and HERV-K replication (Table 1). Because IN 
inhibitors have less side effects compared to RT and pro-
tease inhibitors, it should be an important component in 
any antiretroviral regime.
Our data suggests that similar to HIV antiretroviral 
treatment, complete inhibition of HERV-K may require 
Fig. 5 Modeling of HERV-K protease: a alignment of HERV-K with HIV-1 protease (2HS1) and Rous sarcoma virus protease (1BAI). Red boxes mark 
residues totally conserved in the three sequences and red residues boxed in blue are highly similar residues. b Ribbon representation of the HIV-1 
protease dimer (2HS1) used as a main template in the modeling. Strands are colored in yellow, loop in gray, turn in blue, and α-helices in red. Active 
site residues are represented with their carbon atoms colored in cyan, nitrogen in blue and oxygen in red. c Model of HERV-K protease, carbon atoms 
of the conserved residues of the active site are colored green and non-conserved red
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combination therapy that targets different parts of the life 
cycle of the virus particularly since most of these drugs 
are less potent in their activity against HERV-K compared 
to their effects on HIV. However, studies are needed to 
determine the efficacy of combined inhibitors on HERV-
K replication. Currently, it is not clear if the activation of 
HERV-K expression in ALS patients leads to production of 
infectious viral particles. The anitretrovirals will be effec-
tive only if there was active infection and replication. For 
treatment of ALS patients with antiretroviral drugs, the 
drugs need to have good blood brain barrier penetration to 
target brain neurons with increased HERV-K expression.
Conclusions
We identified that FDA approved RT and IN inhibitors 
can effectively inhibit HERV-K virus, while protease 
inhibitors were not as effective in inhibiting HERV-K 
virus as HIV. Development of new protease inhibitors 
for HERV-K may be required. These antiretrovirals may 
open new prospects for studying HERV-K pathophysiol-
ogy and potentially for exploring treatment of diseases in 
which HERV-K has been implicated.
Methods
DNA constructs and HIV inhibitors
HERV-K whole genome consensus sequence [1] was 
synthesized and cloned into pcDNA3.1 vector (Invitro-
gen). HIV-1 Rev plasmid was reported previously [2]. To 
increase the production of HERV-K viral particles, the 
Rev expression cassette was inserted to the pcDNA3.1-
HERV-K construct. The resulting plasmid was called 
pCD-HK/Rev. All HIV inhibitors and VSV-G plasmid 
were obtained from NIH AIDS reagent program (http://
www.aidsreagent.org). A stock of 10  mM was made by 
Fig. 6 Protease inhibitors duranavir and lopinavir docked to the active site cavity of the viral proteases. a Darunavir (in blue) as in observed in the 
ultrahigh-resolution crystal structure (2HS1) and b Lopinavir (cyan) as bound to HIV-1 protease dimer. The semi-transparent surface of the active 
site cavity is shown using the color of the near atom. Ribbons are colored cyan and pink to represent the different monomers. c, d Models of these 
inhibitors docked to HERV-K protease. Carbon atoms of the HIV-1 protease are colored cyan, the conserved residues in HERV-K instead are colored 
green and the non-conserved red. Oxygen atoms are colored red and nitrogen blue
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diluting the inhibitors in dimethyl sulfoxide (DMSO). 
For further use serial dilutions for each inhibitor was 
made in complete media: Dulbecco’s modified Eagle’s 
medium; DMEM  +  10% fetal bovine serum (FBS) and 
penicillin–streptomycin.
Cell culture and transfection
The human cell lines 293T and Hela were maintained 
in DMEM supplemented with 10% FBS and penicillin–
streptomycin. For testing activity of HIV-RT inhibitors in 
a cell free system, Hela cells were transiently transfected 
with pCD-HK/Rev in 24-well plates at 0.2  ×  106 cells/
well using lipofectamine 2000 (Invitrogen) according to 
the manufacture’s protocol. Virus particle-containing 
supernatants were collected after 24 and 48  h. Control 
experiments included mock transfection with empty vec-
tor pcDNA3.1. Cell culture supernatants were assayed 
for RT activity using a PERT assay as described below. At 
the time of reverse transcription, HIV nucleoside or non-
nucleotide RT Inhibitors were added to the supernatant 
Fig. 7 Protease inhibitors block replication of HERV-K viral particles: HeLa cells were transfected with pCD-HK/Rev and HIV-1 Tat plasmids. a HIV pro-
tease inhibitors were added to Hela cells 6 h post transfection and the reverse transcriptase (RT) activity in the culture supernatant was determined 
by PERT assay at 24 h post-treatment. b Darunavir, Lopinavir, Indinavir, Amprenavir or Atazanavir were added to HeLa cells 6 h post transfection in 
a twofold serial dilution ranging from 31.25 nM to 1 µM and RT activity in the culture supernatant was determined by PERT assay at 48 h post-
treatment. c Darunavir and Lopinavir were further tested using tenfold serial dilution of the compounds, ranging from 100 nM to 100 µM. Viral 
supernatant was collected 48 h post-treatment and analyzed by PERT assay. Any change in Ct (threshold cycle) was compared to vehicle control 
and reported as percent inhibition. Data represent mean ± SEM of at least three different experiments. d, e 293 cells were transfected with pCD-
HK/Rev in the presence or absence of 1 µM Darunavir or Lopinavir. After 48 h, HERV-K viral particles were harvested from the culture medium. The 
expression of Gag in the cell lysate and viral particles was determined by Western blot analysis. Darunavir and Lopinavir effectively blocked the pro-
cessing of Gag (70 kDa) into mature capsid (CA) protein (27 kDa) both in the cell lysate and in the viral particles (d). Viral supernatant was analyzed 
by both PERT assay and viral RNA PCR, indicator of numbers of viral particles. The viral supernatant was also used to infect HeLa cells. After 6 days 
post-infection, HERV-K Gag mRNA in the infected cells was measured by PCR. Values from HERV-K with PI treatment were expressed as percentage 
of that without PI treatment
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at six different doses ranging from 0.001 to 0.25 µM. Any 
change in RT activity was expressed as percent inhibition 
relative to no treatment control.
For testing the activity of HIV protease inhibitors 
against HERV-K, HeLa cells were transiently transfected 
with pCD-HK/Rev as described above. Six hours post-
transfection, culture medium was completely replaced 
with fresh medium containing HIV protease inhibitors in 
a twofold serial dilution ranging from 31.25 nM to 1 µM. 
After 48 h, cell culture supernatants were collected and 
RT activity in the culture supernatant was determined by 
PERT assay. Darunavir and Lopinavir were identified as 
the two most potent drugs and were further screened in 
a tenfold-serial dilution treatment ranging from 0.001 to 
100 µM.
Recombinant virus production and infection
293T cells were cultured in DMEM with 10% FBS and 
penicillin–streptomycin. Cells were transiently trans-
fected in 10  cm plates at 5  ×  106 cells/plate using 
lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s protocol. Briefly, cells were co-transfected with 
pCD-HK/Rev with or without pCD-VSV-G. After 24  h, 
the transfection medium was completely removed and 
cells were washed with phosphate-buffered saline (PBS) 
to eliminate any residual plasmid and then fresh medium 
was added to the cells. Virus particle-containing super-
natants were harvested after an additional 24–48  h and 
cleared of any cellular debris with two centrifugations at 
1000×g at 4 °C. The clarified samples were then subjected 
to DNase treatment using the RNase-free DNase kit 
(Qiagen). Cleared supernatant was concentrated using 
Retro-X™ Concentrator (Clontech) as per manufacturer’s 
instructions. Briefly, viral supernatant was mixed with the 
Retro-X Concentrator and incubated overnight at 4  °C. 
The mixture was then centrifuged at 1500×g for 45 min 
at 4 °C to obtain a virus-containing pellet. The viral pel-
let was gently resuspended using complete DMEM and 
titrated using the PERT assay. An absolute amount of RT 
was determined using HIV RT as standard and 80 pg of 
HERV-K virus was used for each infection. At the time 
of transduction of target cells, the concentrated virus 
was again treated with RNase free DNase to ensure there 
was no plasmid DNA contamination. Infection was per-
formed by exposing the resuspended DNase treated viral 
samples with fresh 293T or HeLa cells that had been 
plated in 24-well plates  24  h earlier in 5  μg/ml of poly-
brene in the presence or absence of Abacavir, Zidovudine 
Fig. 8 Comparative modeling of HERV-integrase active site. a Model of the integrase with the DNA bound. b Alignment between target and 
template was used in the modeling; red boxed residues are identical. c–e The integrase inhibitors mentioned bound to HERV-K integrase active 
site: a Elvitegravir, b Raltegravir were based on the crystal structure of their complexes of PFV (3L2U, 3L2V), and c Dolutegravir. Carbon atoms of 
the enzyme residues are colored green when they are conserved between PFV and HERV-K integrase and red when are not. DNA bases have their 
carbon atoms colored cyan
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or Raltegravir. Total RNA was extracted 6  days post 
infection and HERV-K Gag gene expression was quan-
tified using QPCR. Any change in RT inhibitor treated 
wells compared to untreated was expressed as percent 
inhibition. To determine the effect of protease inhibitors 
on HERV-K infection, 293T cells were transfected with 
pCD-HK/Rev and pCD-VSV-G in the presence of 1 µM 
of Darunavir or Lopinavir. After 24  h, the transfection 
medium was completely removed and cells were washed 
with PBS. Fresh medium with 1  µM of Darunavir or 
Lopinavir was then added back. After another 24 h, viral 
particles were harvested and used to infect 293T cells 
using the same method mentioned above, but without 
any further PI treatment during infection.
RNA extraction and quantitative PCR
Total RNA was extracted from cultured cells with RNe-
asy Plus mini kit (Qiagen) and treated with RNase-
free DNase. Reverse transcription was performed with 
500  ng RNA using Superscript III first stand synthesis 
Supermix kit (Invitrogen). Gene expression levels for 
HERV-K gag and glyceraldehyde 3-phosphotate dehydro-
genase (GAPDH) were determined by quantitative PCR 
performed on an ABI PRISM 7000 Sequence Detection 
System (Applied Biosystem, Carlsbad, California). PCR 
primers are listed in Table 2. Absence of DNA contami-
nation in the RNA preparation was confirmed when tar-
get gene was not detected by PCR when RT was omitted 
during reverse transcription. The amount of RNA was 
expressed as fold change using GAPDH as an internal 
standard.
Product enhanced reverse transcriptase (PERT) assay
PERT assay was used as described [3] with minor modifi-
cations. Briefly, cell culture supernatant was collected and 
centrifuged to pellet any cell debris. The cleared super-
natant was then supplemented with 0.25% Triton X-100, 
5  mM dithiothreitol and 0.25  mM ethylene-diamine-
tetra-acetate as the source of HERV-K RT. Bacteriophage 
MS2 genomic RNA was used as template for the reverse 
transcription reaction. Quantitative PCR was performed 
with TaqMan primers (MS2-Forward and MS2-Reverse) 
and probe (MS2-Probe) using Applied Biosystems Vii 7. 
RT activity was expressed as fold change compared to 
control or as pg/ml RT determined by standard curve 
generated from PERT using HIV-1 RT.
Western blot analysis, immunoflourescence and antibody 
production
For Western blot analysis of HERV-K viral protein 
expression and cleavage, 293T cells were transiently 
transfected with either the HERV-K expression vectors 
or empty vector using lipofectamine 2000 (Invitrogen). 
After 48 h transfection, cells were washed with PBS and 
lysed in radioimmunoprecipitation assay (RIPA) buffer 
containing protease inhibitors (Roche). The insoluble pel-
let was removed by a 10 min centrifugation at 12,000×g. 
The harvested lysates were separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis using Novex 
4–12% Bis–Tris gels (Invitrogen), followed by transfer 
onto polyvinylidene fluoride membranes. The blots were 
incubated overnight at 4  °C with either anti-HERV K 
Env antibody (Austral biologicals) or anti HERV K Gag 
antibody (Austral biologicals) followed by 1 h incubation 
with a secondary antibody linked to horseradish peroxi-
dase. After 30 min washing, the blot was developed with 
SuperSignal™ West Femto ECL reagent (ThermoFisher), 
and imaged with FluoroM imaging machine (ProteinSim-
ple). Immunofluorescence analysis for the co-localization 
of Gag and Pol was performed on 293T cells transiently 
transfected with the HERV-K expression vector or empty 
vector (negative control). Twenty-four hours post-trans-
fection cells were fixed with 4% paraformaldehyde, per-
meabilized, and stained with a rabbit polyclonal anti-Pol 
serum and a mouse monoclonal anti-Gag antibody. Alexa 
488-conjugated goat anti-rabbit IgG and Alexa 594-con-
jugated goat anti-mouse IgG were used as second-
ary antibodies (molecular probes); nuclei were stained 








Abacavir 2.3 µM 0.175 0.006
Zidovudine 0.03 µM 0.070 0.008
Darunavir 2.7–13 nM 0.071 0.029
Lopinavir IC50 17 nM (no serum)
IC50 102 nM (50% 
serum)
0.651 0.034
Raltegravir 0.033 µM 0.075 0.01
Table 2 PCR primers
Target gene Primer sequence (5′–3′)
HERV-K env Forward: CTGAGGCAATTGCAGGAGTT
Reverse: GCTGTCTCTTCGGAGCTGTT







Page 12 of 13Tyagi et al. Retrovirology  (2017) 14:21 
with 4′,6-diamidino-2-phenylindole (DAPI; molecular 
probes).
A polyclonal anti-HERV-K Pol antibody using amino 
acids 57–245 as an immunogen was developed by SDIX 
with its proprietary Advanced GAT technologies. The 
monoclonal antibodies against the full length HERV-
K Env and Gag were obtained from Austral Biologi-
cals. Rabbit antisera against HERV-K envelope protein 
were developed by Genscript, using peptides QRKAP-
PRRRRHRNRC, CSDLTESLDKHKHKK, and CSKRKG-
GNVGKSKRD as immunogens.
Toxicity assay
HeLa cells were cultured in microplates (tissue culture 
grade, 96 wells, flat bottom) in a final volume of 100 µl/
well culture medium in a humidified atmosphere (e.g., 
37 °C, 5% CO2). 24 h later, the cells were treated with HIV 
inhibitors at dosage ranging from 0.01 to 10 µM. Six days 
post-treatment Cell Proliferation Reagent WST-1(Roche) 
was used per manufacturer’s instructions to determine 
drug toxicity. Briefly, 10 µl of Cell Proliferation Reagent 
WST-1 was added to each well and the plate was shaken 
thoroughly for 1  min on a shaker. The cells were incu-
bated for 0.5–4  h in a humidified atmosphere (37  °C, 
5% CO2). The absorbance of the samples against a back-
ground control as blank was measured using a microplate 
reader at 420–480  nm using a FlexStation microplate 
reader (molecular devices).
Comparative modeling
All the comparative modeling was performed using the 
homology modeling protocols implemented in the pro-
gram molecular operating environment (MOE) [22]. The 
sequences of target and templates were initially aligned 
with clustalW [23] and manually adjusted after inspec-
tion to place insertions and deletions in favorable regions. 
An AMBER10HT force field was used for energy calcu-
lations and minimization. Ramachandran’ plot showed 
95% of the residues of the final model are in allowed 
regions, and no rotamer outliers are present. When 
complexes between template and target inhibitors are 
available, the poses of the inhibitors in HERV-K targets 
were based on that of the template’s complexes. When 
required to improve the pose, rotamers of selected resi-
dues 4.5 Å apart from the drug were explored to relieve 
the few clashes observed and to improve contacts, as well 
as drug and nearby residues relaxed by minimization. 
The drug minimization in the active site environment of 
the HERV-K targets was performed, tethering the pro-
tein atoms to their initial position with a weak harmonic 
potential (0.5 kCal/mol) during minimization.
In the case of the protease, the structures of a dimer 
of HIV-1 (PDBId: 2HS1, 0.85 Å) and Rous sarcoma virus 
(RSV; 1BAI, 2.4  Å) proteases were used as templates. 
The RSV protease structure was used to model the inser-
tion in the loop between β4–5 because it displays simi-
lar characteristics to the one in HERV-K protease and, 
the HIV-1 protease was used for the rest of the model 
(Fig. 4b). Three features common to retroviral proteases 
were carefully maintained in the alignment and model: 
(1) the active site triad (26-DTG-28), (2) the highly con-
served triad GRN/D unique to retroviral proteases [24], 
and (3) the intra- and inter-subunit salt bridge between 
R89, D30, and R9′. To model complexes of HERV-K pro-
tease with inhibitors the structures of the highest reso-
lution complexes of the HIV-1 protease with Lopinavir 
(2OS4), and Darunavir (2HS1) were used. Models of the 
complexes with Darunavir and Lopinavir were prepared 
by overlaying the respective complexes structures with 
the HERV-K model.
In the case of the HERV-K RT, HIV-1 RT crystal struc-
ture (4W1E) was used as template, and the crystal struc-
tures of the complexes with Efavirenz (1JKH), Nevirapine 
(3QIP), and Etravirine (3MEC) were used to model the 
inhibitors bound to HERV-K RT.
In the case of the HERV-K IN the simian prototypi-
cal foamy virus in complex with magnesium, DNA, and 
Elvitegravir (3L2U) with an 18% of identity with the tar-
get was used as template. This elvitegravir complex and 
the complexes with ratelgravir (3L2) and dolutegravir 
(3S3M) were used to model these inhibitors complexes 
with HERV-K IN (Fig. 8c–e).
Data analysis and statistics
All the experiments were repeated at least three times. 
Representative results were shown and plotted as 
mean  ±  SEM. Student’s t test was used for pair-wise 
comparison.
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